Elias Molins Grau

Title: Innovations by Elias Molins Grau

Introduction

Elias Molins Grau is a notable inventor based in Sant Feliu de Llobregat, Spain. He has made significant contributions to the pharmaceutical industry, particularly in the development of new polymorphs for medications. With a total of 2 patents, his work focuses on enhancing the stability and production processes of important pharmaceutical compounds.

Latest Patents

One of his latest patents is for a non-hydrated gabapentin polymorph, which includes a production process and its utilization for producing pharmaceutical-grade gabapentin. This polymorph is prepared by drying an aqueous solution of gabapentin through spray drying or turbo-drying. It is utilized in the preparation of pharmaceutical-grade gabapentin by subjecting the polymorph to crystallization from solvents.

Another significant patent is for the paroxetine maleate polymorph and pharmaceutical compositions containing it. The form B of paroxetine maleate polymorph is characterized by specific data from X-ray diffraction, demonstrating superior chemical stability compared to form A. This enhanced stability allows for the new polymorph to be used in the fabrication of medicaments aimed at treating disorders related to dysfunctions of the central nervous system. The production process for paroxetine maleate involves preparing a paroxetine maleate solution followed by a precipitation step.

Career Highlights

Elias Molins Grau is associated with Medichem, S.A., a company known for its focus on pharmaceutical development. His work at Medichem has allowed him to contribute to advancements in drug formulation and stability.

Collaborations

He has collaborated with notable coworkers such as Jordi Bosch Lladó and Maria Del Carmen Onrubia Miguel, enhancing the innovative efforts within his team.

Conclusion

Elias Molins Grau's contributions to the field of pharmaceuticals through his patents reflect his commitment to innovation and improvement in medication stability and production processes. His work continues to impact the pharmaceutical industry positively.